Contract research organizations (CROs) must respond to the global COVID-19 pandemic with digital clinical trial solutions to support biopharma companies’ research continuity initiatives as well as provide more infrastructure to ensure patient safety.
PPD is one of the largest CROs in the market and recently touted their digital clinical trial offerings—from electronic patient consent to telehealth to hybrid and fully centralized/clinical trials. Their goal: enable biopharmaceutical companies to advance current and planned clinical research programs.
With the advent of the pandemic, much economic activity came to a grinding halt. Hence, the coronavirus pandemic posed greater challenges to the design and conduct of clinical trials, particularly the inability of some patients to visit impacted research sites when subject to government stay-at-home orders or to avoid exposure risk.
Niklas Morton, PPD’s senior vice president of digital services, commented, “The pandemic’s impact is driving a new consensus that the need is now for expanded use of digitally enabled trials.”
A CROs Response
PPD had long ago been seeking digital strategies for enabling more...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).